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Abstract
Background: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system
in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the
brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to
antidepressant treatment.
Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398
depressed Caucasian inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Two
Caucasian replication samples (N= 249 and N= 247) were investigated, resulting in a total number of 894 patients. 18
tagging SNPs in the BDNF gene region and 64 tagging SNPs in the NTRK2 gene region were genotyped in the discovery
sample; 16 nominally associated SNPs were tested in two replication samples.
Results: In the discovery analysis, 7 BDNF SNPs and 9 NTRK2 SNPs were nominally associated with treatment response. Three
NTRK2 SNPs (rs10868223, rs1659412 and rs11140778) also showed associations in at least one replication sample and in the
combined sample with the same direction of effects (Pcorr= .018, Pcorr= .015 and Pcorr= .004, respectively). We observed an
across-gene BDNF-NTRK2 SNP interaction for rs4923468 and rs1387926. No robust interaction of associated SNPs was found
in an analysis of BDNF serum protein levels as a predictor for treatment outcome in a subset of 93 patients.
Conclusions/Limitations: Although not all associations in the discovery analysis could be unambiguously replicated, the
findings of the present study identified single nucleotide variations in the BDNF and NTRK2 genes that might be involved in
antidepressant treatment outcome and that have not been previously reported in this context. These new variants need
further validation in future association studies.
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Introduction
Despite large efforts during the last decades, antidepressant
treatment efficacy in depression is still unsatisfactory [1,2]. While
antidepressants are generally effective and indispensable for the
treatment of moderate and severe depression, up to two of three
patients do not sufficiently respond to a first antidepressant
treatment attempt [2]. Increased plasma corticosteroid levels,
typically found in many patients with depression [3], may lead to a
reduced trophic support of neurons and an impaired plasticity of
critical brain structures involved in affective disorders [4,5]. Stress-
induced perturbation of hormonal homeostasis, and specifically
elevated corticosteroid concentrations decrease the expression of
hippocampal brain-derived neurotrophic factor (BDNF) [6,7], a
major mediator of neurogenesis and synaptic plasticity involved in
learning and adaptive processes in the adult brain [8]. As
antidepressants have been shown to reverse stress and depression
induced BDNF downregulation and impaired neurogenesis [9,10],
BDNF has been implicated in recovery mechanisms from
depression, which resulted in the neurotrophin hypothesis of depression
[4,5]. In several studies, reduced serum BDNF levels in depression
and reduced hippocampal BDNF expression in mouse models of
affective disorders could be reversed by various antidepressant
interventions [4,5,11–13].
Apart from BDNF, the neurotrophin system comprises the
nerve growth factor (NGF), neurotrophin 3 and 4/5, as well as
their key receptors, the tropomycin receptor kinase (Trk) family,
including the major receptor for BDNF, TrkB, encoded by the
NTRK2 gene [11]. Indeed, functional BDNF-TrkB signaling is
required for behavioral effects induced by antidepressants [14] and
increased NTRK2 mRNA expression [15] and signaling [14,16,17]
upon antidepressive interventions have been recently reported.
Thus, these two genes are in the focus of this study.
Up to now, pharmacogenetic studies on polymorphisms in the
neurotrophin system nearly exclusively focused on the BDNF gene,
especially the non-synonymous Val66Met (rs6265) polymorphism.
Despite several attempts to replicate initial associations, many
conflicting results have been reported on this polymorphism
[18,19], which could at least in part be related to population effects
[20]. Despite some positive associations reported for other BDNF
and NTRK2 SNPs [21,22], previous pharmacogenetic studies did
not find a major impact of BDNF and NTRK2 polymorphisms on
antidepressant treatment including a German [23] and the
STAR*D sample [24]. Presently there are no SNPs of the
neurotrophin system that have been unambiguously shown to be
associated with treatment response in depression.
We extended the previous approaches by testing pharmacoge-
netic associations not only for variants in the BDNF gene but also
for variations in its main receptor gene, NTRK2, in depressed
German inpatients participating in the Munich Antidepressant
Response Signature (MARS) project, which is a naturalistic study
dedicated to identify predictors of antidepressant treatment
outcome. We selected 82 tagging SNPs covering 100% of BDNF
variants with a minor allele frequency (MAF) $0.01 and 92.8% of
NTRK2 variants with a MAF $0.1 based on HapMap project
data. We tested all nominally significant SNPs out of the discovery
analysis in 2 replication samples, resulting in a total sample size of
894 patients. In addition to our single-marker analysis we
performed multi-marker approaches using a haplotype as well as
a two-way interaction analysis.
Methods
Ethics Statement
The study was approved by the Ethics Committees of the
Medical Faculties at the Ludwig Maximilians University, Munich,
Germany, and at the University of Muenster, Muenster,
Germany, respectively. Written informed consent was obtained
from all subjects, and the study was carried out in accordance with
the latest revision of the Declaration of Helsinki.
Sample Description
398 Caucasian inpatients (56.0% females, mean age 49.1614.4
(SD) years) that participated in the MARS project (http://www.
mars-depression.de) were included within 5 days after admission to
the clinic for the treatment of an acute depressive episode, as
described in detail previously [1]. Depressive symptoms were rated
weekly with the 21-items version of the Hamilton Rating Scale for
Depression (HAM-D) and all patients were at least moderately
severe depressed at inclusion (HAM-D $14). Two replication
samples were defined: (1.) 249 newly recruited participants of the
MARS project (MARS replication; 51.4% females, mean age
48.0613.6 (SD) years), and (2.) 247 of 340 Caucasian inpatients
with an HAM-D $14 at inclusion recruited in a pharmacogenetic
study at the University of Muenster, Westphalia, Germany [23,25]
(Muenster replication; 59.1% females, mean age 49.2614.9 (SD)
years; see Table 1). MARS patients (N=647) suffered from a single
major depressive episode (single MDE; 32.9%), recurrent
depression (RD; 56.1%) or bipolar depression (BP; 11.0%).
Among MARS bipolar patients, 42.6% (29 of 68) were
subclassified as bipolar type 1 and 57.4% (39 of 68) as bipolar
type 2. All patients received antidepressant treatment according to
the choice of the attending doctor with antidepressant dosages
adjusted according to therapeutic plasma level ranges. In
accordance with previous studies from the MARS project [1,26–
30], response was defined as an at least 50% reduction after five
weeks of the HAM-D score at admission. Remission at discharge
was defined as a HAM-D ,10 (mean duration of hospital stay:
11.567.8 (SD) weeks).
DNA Sampling and SNP Genotyping
DNA was extracted from 30 ml of EDTA blood using Puregene
whole-blood DNA extraction kits (Gentra Systems, Minneapolis,
USA). Using the Tagger software implemented in the HapMap
project browser (de Bakker, et al 2005), we retrieved tagging SNPs
for the longest BDNF isoform (NM_170731, 66.86 kb; 18 SNPs)
and the full-length NTRK2 gene (NM_006180, 355.04 kb;
64 SNPs), flanked by additional 20 kb of both 59 and 39 sequences
according to Human HapMap Project Phase I and II data for the
CEU population, leading to 100% and 92.8% SNP marker
coverage, respectively. Pair-wise r2 for a bin of linked SNPs was set
to $0.8. The minor allele frequency (MAF) was set to $0.01
(BDNF) and $0.1 (NTRK2), respectively. MARS patients were
genotyped using Sentrix Human-1 100 k, HumanHap 300 k and
Human610 Genotyping BeadChips (Illumina Inc., San Diego,
USA) and MALDI-TOF mass-spectrometer (MassArrayH system),
as described previously [31]. Patients form the Muenster sample
were genotyped using the MALDI-TOF mass-spectrometer. In
case of insufficient genotyping quality (defined as an experiment-
wise call rate ,.97 or significant deviation from the Hardy-
Weinberg equilibrium, HWE), melting curve analysis using real-
time PCR was performed (rs11602246, rs1659412, rs2049046,
rs1491850 in the Muenster replication sample; rs11140778 in the
MARS replication sample). SNPs that entered analysis did not
significantly deviate from HWE (Table 2, S1, S2) using a
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Bonferroni-corrected.05 level of significance (a= .05/
82= 6.161024).
Protein Analysis
Morning fasting serum was available in 93 MARS patients at
admission and after 6 weeks of treatment (mean 6.2+/21.6 weeks)
as well in 97 age- and gender-matched healthy controls derived
from a German sample recruited at the Max Planck Institute of
Psychiatry, Munich. Among patients, 47 were classified as
remitters and 65 as responders according to the above mentioned
criteria. Serum total BDNF levels were assessed with an enzyme-
linked immunoabsorbant assay (ELISA) kit (Promega BDNF
EmaxH, Madison, Wis.). All measurements were performed in
Table 1. Sample characteristics.
All patients MARS Discovery MARS Replication Muenster Replication
N=894 N=398 N=249 N=247 Pa
Age, mean (SD), y 48.9 (14.3) 49.1 (14.4) 48.0 (13.6) 49.2 (14.9) .58
Female gender, No. (%) 497 (55.6) 223 (56.0) 128 (51.4) 146 (59.1) .22
Unipolar depression, No. (%) 780 (87.2) 345 (86.7) 231 (92.8) 204 (82.6) ,.01
HAM-D at admission, mean (SD) 25.9 (6.6) 24.4 (6.4) 27.1 (5.8) 24.0 (7.2) ,.001
HAM-D at discharge, mean (SD) 7.6 (6.0) 9.1 (5.9) 7.1 (6.2) 5.8 (5.2) ,.001
Duration of hospital stay (weeks), mean (SD) 11.5 (9.2) 11.5 (7.8) 10.9 (9.0) 12.0 (11.5) .45
Response at week 5, No. (%) 468 (52.3) 192 (50.1) 147 (63.4) 129 (53.1) .01
Remission at discharge, No. (%) 581 (65.0) 204 (60.7) 172 (72.9) 202 (81.8) ,.001
Number of previous episodes, mean (SD) 3.01 (5.4) 2.84 (5.1) 3.51 (7.3) 2.76 (2.8) .27
Duration of current episode (weeks), mean (SD) 38.12 (66.0) 41.37 (71.4) 32.63 (55.2) N/A .11
Psychotic symptoms, No. (%) 87 (13.6) 50 (12.6) 37 (15.4) N/A .31
Treatment resistanceb at admission, No. (%) 94 (16.7) 54 (15.4) 40 (18.9) N/A .28
aANOVA and Chi-square, respectively, comparing the different samples. For some variables there are missing data and N does not equal number of total patients.
Percentages are based on available data.
bTreatment resistance was defined as at least 2 antidepressant treatment attempts with an adequate duration and dosage according to Souery et al.
N/A: data not available.
doi:10.1371/journal.pone.0064947.t001
Table 2. Nominally associated BDNF and NTRK2 SNPs in the MARS discovery sample.
SNP Gene Functiona
Minor/major
allele Genotype MAF HWE Pb Pc (allelic) Pc (genotypic)
1/1 1/2 2/2
rs2049048 BDNF 5’ T/C 277 110 11 .17 ..99 .014 .008
rs1491850 BDNF 5’ C/T 122 189 87 .46 .42 .009 .03
rs4923468 BDNF intron A/C 388 10 0 .01 ..99 .01 ..99
rs2049046 BDNF intron A/T 133 175 90 .45 .03 4.8861025 4.6661024
rs6265 BDNF Val66Met A/G 242 127 29 .23 .04 .04 .07
rs11602246 BDNF 3’ G/C 322 69 7 .10 .17 .009 .034
rs11030094 BDNF 3’ A/G 140 178 80 .42 .10 1.5261024 6.0561024
rs10868223 NTRK2 5’ T/C 308 82 8 .12 .35 .03 .11
rs1659412 NTRK2 5’ C/T 320 63 7 .10 .08 .02 .08
rs1662695 NTRK2 intron C/T 301 93 4 .13 .37 .04 .11
rs11140778 NTRK2 intron T/A 247 133 18 .21 ..99 .004 .01
rs2277193 NTRK2 intron C/T 205 155 35 .28 .46 .02 .08
rs1948308 NTRK2 intron C/T 123 202 73 .44 .61 .008 .008
rs17418241 NTRK2 intron T/C 331 65 2 .09 .75 .04 .09
rs1387926 NTRK2 intron A/G 301 93 3 .12 .17 .047 .08
rs1490402 NTRK2 3’ G/A 295 98 5 .14 .40 .009 .01
aAccording to dbSNP build 132.
bUncorrected P values for the deviation from Hardy-Weinberg-Equilibrium; note that no P value exceeded the corrected (82 SNPs, Bonferroni) threshold of p,6.161024.
cNominal P values for associations with response after 5 weeks (strongest phenotype in the discovery sample).
doi:10.1371/journal.pone.0064947.t002
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duplicates and mean values were taken for further analysis (mean
difference between unicates was 6.5% +/26.1 SD).
Power Calculation
The CaTS Power Calculator for Genetic Studies [32] was used
for power calculation using a two-stage design. The experiment-
wise alpha error was set to 6.161024 according to a Bonferroni-
correction for 82 investigated SNPs. Given a predicted response
rate to antidepressant treatment of 50% in an inpatient setting
after 5 weeks [1], we calculated that a total sample size of N=880
is sufficient to achieve a power of at least 90% (additive model) to
detect genetic effects in a joint analysis of the discovery and
replication samples assuming a relative risk of 1.40 or larger for
SNPs with an allele frequency of at least 10%. If a multiplicative
model is assumed, as it is proposed for complex diseases [33], a
power of 93% can be expected. We can conclude from this power
analysis that the combined sample size of the present study
(N= 894) should be sufficient for detecting small to moderate
effects of the investigated polymorphisms.
Statistical Analysis
Genetic association analysis with binary response variables
(response at week 5 and remission at discharge) was performed by
X2 statistics using the WG-Permer software (http://www.
mpipsykl.mpg.de/wg-permer) with allelic and genotypic models.
For all association tests, the level of significance was set to.05, and
P values were corrected for multiple comparisons using a
resampling method as proposed by Westfall and Young [34]
applying 105 permutations over all performed tests (i.e., for
82 SNPs analyzed in the discovery sample and for 16 SNPs
analyzed in the replication or in the combined sample). Empirical
P values were obtained using the Monte Carlo method
implemented in the WG-Permer software to approximate the
exact P value with the given standard distribution without relying
on asymptotic distributional theory [35].In case of a significant
association, the Armitage’s test for trends [36] was calculated using
the software provided by the Institute for Human Genetics,
Munich (http://ihg2.helmholtz-muenchen.de) and confidence
intervals were calculated using a log-normal distribution. Forest
plots were drawn using the rmeta software package for R-2.5.0
(http://cran.r-project.org). In the replication study, we used Fisher
products [37] corresponding to the geometric mean of the P values
of the two response variables (i.e. response after 5 weeks and
remission at discharge) to account for possible sample heteroge-
neity. We defined successful replication as a nominal association in
one of the replication samples and same direction of the effect.
Group differences in demographic and baseline clinical data
were compared using Pearson x2 test in case of qualitative data
and with t-tests for independent samples in case of quantitative
data. Average change during treatment outcome was evaluated
with t-tests for paired samples. Additionally, an analysis of
covariance was applied to evaluate the effects of treatment
outcome (response, remission) on BDNF serum protein concen-
tration with age, sex, and baseline BDNF as covariates. A logistic
regression analysis was applied for evaluating SNP6protein
interactions as a predictor for response or remission, respectively)
using age and sex as covariates. All statistical analyses were
conducted with SPSS for Windows (version 18.0, SPSS, Chicago,
USA).
Haplotype Association Testing
The phenotype showing the strongest effect in the single-marker
association analysis was further investigated in a haplotype analysis
using the Haploview 4.1 software [38]. In order to detect
informative associations complementary to our tagging SNP
approach, haplotype analysis was performed using a D’-based
linkage disequilibrium (LD) map based on haplotype blocks
defined according to Gabriel et al. [39] (Figure S1). Analysis was
performed in the discovery sample providing sufficient marker
coverage. We used 105 random permutations implemented in
Haploview to control for false-positive findings. Rare haplotypes
(frequencies ,.01) were excluded from the analysis. We report P
values for at least nominally significant haplotypes.
Interaction Analysis
In the combined sample, we analyzed all possible two-way
interactions across both genes (7 BDNF69 NTRK2 SNPs) and
between the phenotype showing the strongest effect in the single-
marker association analysis using a Bonferroni-corrected.05 level
of significance (a= .05/63= 7.961023). The interaction analysis
was performed with a step-wise logistic regression using R-2.5.0
(http://cran.r-project.org). Age, sex and sample origin were
included as covariates, and genotypes were coded following an
allelic model to obtain maximal power.
Linkage Disequilibrium Mapping
We used the Haploview 4.1 software to map the r2-based LD
pattern from the CEU population (release 21). Haplotype blocks
were defined according to the method of Gabriel et al. [39]. Using
the SNP Annotation and Proxy Search (SNAP) program provided
by the BROAD Institute (http://www.broadinstitute.org/mpg/
snap), we further tested, whether the four SNPs that withstood
correction for multiple testing in our combined analysis
(rs2049046, rs10868223, rs1659412, rs11140778) were in gene-
wise LD (within the BDNF and NTRK2 gene, respectively) with at
least nominally associated SNPs reported in previous studies [21–
23,40–42]. We used the 1000 Genomes Project Data set
implemented in SNAP to retrieve LD informations of recently
identified SNPs (e.g. rs61888800). We found only the BDNF SNP
rs2030324, previously reported by Licinio [22], to be in high LD
(r2 = .90) with rs2049046 of the present study. Neither for any
other BDNF (rs7124442, rs61888800, rs908867) nor NTRK2 SNP
(rs1187362, rs1187327, rs2289656, rs2378672, rs7020204,
rs2013566, rs11140793) annotated in the data set, we could
identify proxies with an r2$.80.
Results
Association Analysis with Antidepressant Treatment
We tested the association between 18 BDNF and 64 NTRK2
tagging SNPs with response after week 5 and remission at
discharge in the MARS study sample (N=398). The strongest
associations were found for response after 5 weeks and under an
allelic model (Tables S1 and S2). Seven SNPs in the BDNF gene
and nine SNPs in the NTRK2 gene were nominally associated with
Figure 1. Development of HAM-D values during antidepressive treatment depending on the rs10868223 (A), rs1659412 (B) and
rs11140778 (C) genotype (combined sample). Repeated measurements (Greenhouse-Geisser, age and sex as covariates) revealed significant
interaction effects for rs10868223 (P= .007) and rs1659412 (P= .012), but not for rs11140778 (P= .645). Stars indicate significant between-subjects
differences at different time points (*, p,.05; **, p,.01; GLM with age and sex as covariates). Error bars are standard errors of the means.
doi:10.1371/journal.pone.0064947.g001
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the strongest associated phenotype (response after 5 weeks). In the
BDNF gene region, four SNPs were located in untranslated regions
(two 59 and two 39 UTRs), two within introns, and one SNP
(rs6265) within an exon resulting in a valine-methionine amino
acid exchange (Val66Met, Table 2 and Figure S2a,b). The
strongest associations were found for rs2049046 (intronic;
P=4.961025) and rs11030094 (39 UTR; P=1.561024). In the
sample analyzed, both SNPs were in strong LD (r2 = .92). Within
the NTRK2 gene, the intronic SNP rs11140778 (P=4.1261023)
showed the strongest association with response after 5 weeks.
Replication Studies
In order to replicate these findings we genotyped the 16 SNPs
showing nominally significant associations for the strongest
phenotype (response after 5 weeks) in the MARS discovery sample
in two replication samples. Although all patients fulfilled the same
inclusion criteria (at least moderate depressive episode: HAM-
D$14) and did not differ in baseline demographics, there were
significant differences in baseline depression severity and response
to antidepressant treatment between the three samples (Table 1).
In particular, patients in the Muenster replication sample had a
lower HAM-D at baseline compared to the discovery sample
(P,.001; Bonferroni post-hoc test). Both replication samples had
lower HAM-D scores at discharge than the discovery sample
(P,.001, each; Bonferroni post-hoc test). Highest remission rates at
discharge were observed in the Muenster sample, whereas highest
response rates after week 5 were found in the MARS replication
sample. To better account for this sample heterogeneity, we used
Fisher Products [37] of these two phenotypes (i.e. response after 5
weeks and remission at discharge) in subsequent analyses of the
replication samples (referred to as ‘outcome’ if not otherwise
specified).
Treatment outcome was tested in replication samples under the
allelic model, which showed the strongest associations in the
discovery sample. Of the 16 nominally associated SNPs in the
discovery sample, we found one BDNF SNP (rs11602246; P= .01)
and one NTRK2 SNP (rs10868223; P= .009) to be nominally
associated with outcome in the MARS replication sample
(N=249). In the Muenster replication sample, the three NTRK2
SNPs rs1659412, rs1662695 and rs11140778 showed nominal
associations (P= .01; P= .03; P= .003, respectively). In the
combined analysis of all patients across the three samples we
found the SNPs rs2049046 (BDNF; Pcorr= .021), rs10868223
(NTRK2; Pcorr= .018), rs1659412 (NTRK2; Pcorr= .015) and
rs11140778 (NTRK2; Pcorr= .004) to be significantly associated
with response after correction for multiple testing (Table 3,
Figure 1). According to our definition of a positive replication, we
could replicate the three NTRK2 SNPs (rs10868223, rs1659412
and rs11140778) as they showed associations in at least one
replication sample and had a lower P value in the combined
analysis compared to any single sample of the study, withstanding
correction for multiple testing. For these three markers, we
calculated the Armitage test of trends as a measure of the effect
size separately in the three different samples and for both
phenotypes (Figure 2). Under the definition for a replication, the
most significantly associated BDNF marker in the discovery
sample, rs2049046 could not be replicated, although the
association in the combined analysis still withstood correction for
multiple testing (Pcorr= .02).
As the results of single SNP associations might be confounded
by combining patients with bipolar and unipolar depression, we
reanalyzed the combined sample for unipolar depressed patients
only (N=780; 16 SNPs). Again, rs10868223, rs1659412 and
rs11140778 showed the strongest association with outcome
withstanding correction for multiple testing (Pcorr= .009, Pcorr= .04
and Pcorr= .012, respectively).
Medication- and Gender-specific Associations
Stratifying the patients in the combined sample according to
their antidepressant medication (tricyclic antidepressants, TCA;
serotonin-noradrenaline reuptake inhibitors, SNRI;noradrenergic
specific-serotonergic antidepressants, NASSA; noradrenaline re-
uptake inhibitors, NARI; monoaminoxidase inhibitors, MAOI
and others) revealed SSRI-specific associations for rs2049046
(BDNF) and rs11140778 (NTRK2). Co-medication of mood
stabilizers, benzodiazepines and lithium did not reveal genotype-
dependent differences in prescription rates for these SNPs.
Gender-specific effects were observed for rs11140778 (males)
and rs1659412 (females) (Tables S3–S5; Document S1).
Haplotype Association Testing
We performed a haplotype-based association analysis to test for
informative associations complementary to our single marker
approach using the discovery sample providing sufficient marker
coverage (82 SNPs, best phenotype of the single marker analysis in
this sample (response after week 5), allelic model). Nine of twenty
D’-based haplotype blocks (2 in the BDNF and 7 in the NTRK2
gene, respectively; Figure S1) contained nominally significant
haplotypes, most of them including SNPs that had been nominally
associated in the single marker analysis of both, the discovery as
well as the combined sample (Figure 3, Table S6). The GC
haplotype of block 1 (rs1030094, rs11602246) and the GGGACT
haplotype of block 3 (r6265, rs11030109, rs10835211, rs2049046,
rs4923468 and rs12273363), both within the BDNF gene, showed
a significant association withstanding a permutation-based cor-
rection for multiple testing (Pcorr = 7.4610
23 and
Pcorr = 7.3610
23, respectively).
Interaction Analysis
We performed gene-wise logistic regression for each pair of
7 BDNF and 9 NTRK2 SNPs genotyped in the combined sample,
including age, sex and sample origin as covariates. Given a
Bonferroni-based threshold of significance for 769= 63 statistical
tests (a=7.961023), the interaction of the BDNF SNP rs4923468
with the NTRK2 SNP rs1387926 showed a significant association
with outcome (P=4.661023). No other pairs of BDNF and
NTRK2 SNPs showed associations.
BDNF Protein Analysis
In order to evaluate the potential functional impact of the
associated polymorphisms, we measured BDNF serum protein
concentration in 93 unselected MARS patients with available
blood samples at admission and after antidepressant treatment.
Compared to 97 age- and sex-matched healthy controls, no
difference in baseline BDNF concentration could be observed
(22.13 ng/ml +/29.98 SD (patients) vs. 22.49 ng/ml +/
29.74 SD (controls); P= .803). Also during antidepressant treat-
ment, no change in average BDNF levels was found (22.13 ng/ml
+/29.98 SD vs. 23.19 ng/ml +/210.00 SD; P= .258, paired t-
test). However, when considering antidepressant treatment out-
come in terms of remission status, we observed a significant effect
on the BDNF concentration after treatment (P= .024) with higher
BDNF concentration levels in remitters. No effects were detected
for response status (P= .279). When testing the moderating effects
of NTRK2 SNPs showing a replicated effect on treatment outcome,
we observed a genotype6protein (after treatment) interaction for
rs10868223 with remission (P= .019) and for rs11140778 with
BDNF and NTRK2 and Antidepressant Treatment
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response (P= .038) (see Figure S3). These effects were significant at
the nominal level, not surviving correction for multiple testing.
Further, interrogating a publicly available expression quantita-
tive trait loci (eQTL) database (GENEVAR; [43]) for the three
NTRK2 SNPs in the combined analysis with transcripts of either
BDNF or NTRK2, we found nominal associations for rs11140778
and rs10868223 with two BDNF transcripts (GI_34106709-A, and
Figure 2. Forest plots for the three replicated NTRK2 SNPs rs10868223 (A), rs1659412 (B) and rs11140778 (C). For each sample, odds
ratios and P values calculated with the Armitage’s test are indicated separately for the two phenotypes remission at discharge (blue boxes) and
response after week 5 (pink boxes). Diamonds were used for the combined sample (N= 894).
doi:10.1371/journal.pone.0064947.g002
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GI_34106708-I; P= .03 and P= .03) not withstanding correction
for multiple testing.
Discussion
This pharmacogenetic study investigated the association of
18 BDNF and 64 NTRK2 tagging SNPs with antidepressant
treatment outcome in a representative sample of Caucasian
inpatients. We tested all 16 nominally significant SNPs of the
discovery analysis in 2 replication samples, resulting in a total
sample size of 894 patients.
We found 3 NTRK2 SNPs (rs10868223, rs1659412 and
rs11140778) showing associations in the discovery and at least
one replication sample as well as in the combined sample of 894
patients with a lower P value as compared to the discovery sample
and withstanding correction for multiple testing. None of these
NTRK2 markers has been investigated in pharmacogenetic studies
so far. Nevertheless, the functional impact of these non-coding
SNPs remains unclear as robust association could neither be found
in our protein analysis nor in a publicly available eQTL database.
NTRK2 polymorphisms have so far been studied for association
with childhood-onset mood disorders [40,44], Alzheimer’s disease
[45], suicidality [31,46] and antidepressant response [21,24,47].
Dong and colleagues [21] found two NTRK2 coding SNPs
(rs2289657 and rs56142442) to be associated with response in a
Mexican American MDD sample (N=272), whereas association of
NTRK2 SNPs was neither found in the GENDEP [47] nor the
STAR*D sample [24]. The significant NTRK2 SNPs found in the
present study are located 59 of the transcriptional unit (rs10868223
and rs1659412) and in an intron (rs11140778). They are not in LD
with previously reported NTRK2 SNPs. In addition, as previous
studies did not tag regions far outside the coding regions,
rs10868223 and rs1659412 could not have been detected so far.
Similarly to previous studies that report interactive
BDNF6NTRK2 interaction on the SNP level for geriatric
depression [48] and suicidality [31,46], we found a BDNF6NTRK2
SNP interaction for antidepressant treatment outcome in the
present study. The findings of our interaction study have to be
interpreted cautiously as only nominally associated SNPs from the
Table 3. Association with Treatment Outcome.
MARS Discovery MARS Replication Muenster Replication Combined Sample
N=398 N=249 N=247 N=894
SNP Gene Pa Pa Pa Pa Pb
Beneficial
allele
rs2049048 BDNF .052 .33 .05 .019 .24
rs1491850 BDNF .002 .64 .75 .06 .54
rs4923468 BDNF .046 n.p.c .59 .60 ..99
rs2049046 BDNF 1.061025 .93 .82 .002 .021 T
rs6265 BDNF .10 .17 .64 .07 .60
rs11602246 BDNF .014 .010 .64 .32 .99
rs11030094 BDNF 9.061025 .70 .73 .016 .19
rs10868223 NTRK2 .039 .009 .49 .002 .018 C
rs1659412 NTRK2 .041 .41 .010 .001 .015 C
rs1662695 NTRK2 .077 .72 .032d .038 .42
rs11140778 NTRK2 .014 .10 .003 1.861024 .004 A
rs2277193 NTRK2 .13 .09 .60 .61 ..99
rs1948308 NTRK2 .009 .08 1.00 .013 .19
rs17418241 NTRK2 .025 .29 .72 .54 ..99
rs1387926 NTRK2 .021 .36 .76 .30 .99
rs1490402 NTRK2 .004 .21 .91 .08 .70
aEmpirical P values for the associations with treatment outcome (FPM analysis) under an allelic model.
bP value, permutation-based correction for multiple testing (16 SNPs).
cNot polymorphic.
dNote that this P value would not fulfill a more conservative threshold of alpha = .025 correcting for the fact that two replication samples have been analyzed.
doi:10.1371/journal.pone.0064947.t003
Figure 3. Significant haplotype blocks, both located in the
BDNF gene, which showed association with response after 5
weeks (best phenotype of the single marker analysis). Note, that
for optimal gene coverage, haplotype analysis was performed in the
discovery sample only (N= 398, 82 SNPs).
doi:10.1371/journal.pone.0064947.g003
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initial sample entered the analysis and we corrected the p-value
only for this subset of SNPs. Future studies, including SNP6SNP
and SNP6protein analyses, need to substantiate these initial
findings and may help elucidating the complex interplay of BDNF
and its main receptor TrkB.
It has been suggested that various antidepressants may act
differentially on the neurotrophin system [49] and pharmacoge-
netic associations may be restricted to specific drug treatments
[22]. In the BDNF gene, Dwivedi et al. found a desipramine-
specific increase in exons I and III mRNA in both the frontal
cortex and hippocampus, whereas fluoxetine increased only exon
II mRNA in the hippocampus [49]. Similarly, we found a
differential pattern of associated SNPs dependent on the type of
antidepressant in our study. In particular, the intronic BDNF SNP
rs2049046 and the NTRK2 SNP rs11140778, both significantly
associated in the combined sample, may exert their effects on
response via SSRI-mediated mechanisms. We found that the
strong association of rs2049046 in the discovery sample is related
to SSRI treated patients only. Interestingly, Domschke et al. [23]
described a SSRI-specific association for the BDNF SNP
rs7124442, and most previous studies showing pharmacogenetic
associations with BDNF included SSRI treated patients only
[19,50–52]. However, Licinio et al. [22] described an intronic
BDNF SNP to be nominally associated with response in a
desipramine treated, but not a fluoxetine treated subgroup of
Mexican Americans. Our own results do not contradict the
hypothesis of medication-specific effects of BDNF polymorphisms
upon treatment outcome. To further substantiate this assumption,
larger samples with a randomized parallel group design are
necessary.
Although our study was sufficiently powered to detect small to
moderate genetic effects, we could not resolve the ambiguity of
pharmacogenetic findings for BDNF. Several clinical and preclin-
ical studies have assigned a major impact of BDNF in the
pathophysiology of depression and its recovery mechanisms, while
pharmacogenetic and case-control studies on BDNF polymor-
phisms have produced conflicting results [19,22–24,41,47,50–56].
In particular, a recent meta-analysis including a total of
2812 MDD patients and 10843 controls did not find an
association of the functional Val66Met (rs6265) polymorphism
with unipolar depression in the total sample, but in a separate
analysis of male participants [57]. Similarly, no consistent case-
control association could be demonstrated in bipolar depression
[42,58–61]. Considerable global population diversity of BDNF
allele and haplotype frequencies have been held responsible for
these inconsistencies across studies [20].
In an extensive exonic analysis including novel sequence
variants in a Mexican American sample, Licinio et al. [22]
detected eight nominally significant markers associated with
response. Interestingly, one of them, rs2030324 is located in the
same LD block as rs2049046 in the CEU population (SNP’s pair-
wise r2 = 0.9) that showed significant association in the combined
sample of the present analysis. Nevertheless, the SNP was not
associated in our replication samples. Using different BDNF SNPs,
one of our replication samples was previously analyzed by
Domschke and coworkers [23] who found a negative effect of
the BDNF SNP rs7124442 TT genotype on treatment outcome
(N=254), particularly in anxious depression. Nevertheless, as the
analysis of 10 SNPs including rs6265 in outpatients genotyped in
the STAR*D sample did not show any significant association with
response, the authors concluded that the BDNF gene does not have
major impact on antidepressant treatment response and only a
potential minor role in the context of melancholic depression [23].
Concerning BDNF, this is in line with findings from the present
study.
A gender-specific stratification of our sample indicates that the
strong association of the NTRK2 SNP rs11140778 in the combined
sample mainly originates from the male subgroup of patients. On
the other hand, rs1659412, also significantly associated in the
combined sample, appears to moderate antidepressant response
predominantly in female patients. Of note, both SNPs did not
even show nominal associations in the opposing gender. Gender-
specific effects have been reported for BDNF associations with
depression and antidepressant treatment [23,57], as well as for
NTRK2 with obsessive-compulsive disorder [44]. Nevertheless,
results have to be interpreted cautiously and subsamples might still
have been underpowered to rule out false-negative associations.
Several limitations of the present study should be mentioned.
First, although our power analysis suggested being sufficient to
detect moderate genetic effects in the combined sample, the study
might still have been underpowered for statistical effects in
complex phenotypes like antidepressant response possibly ac-
counting for the lack of replication of BDNF associations found in
the discovery sample. Another issue are the multiple statistical tests
performed in this study including several post-hoc analyses. Thus,
although having corrected for the number of SNPs genotyped,
reported association may still have been found just by chance. In
addition, at least part of the patients have been also analyzed on
genome-wide level [29] without significant association of BDNF
and NTRK2 polymorphisms. Nevertheless, the current study
follows a candidate gene approach with selectively genotyped
SNPs. Conversely, a random selection of 82 SNPs genotyped in
325 patients in the discovery sample using Human610 Genotyping
BeadChips (165 responder, 160 non-responder) resulted in only
two nominal significant associations (P= .003 and P= .026,
respectively), not withstanding correction for 82 SNPs investigated
(P= .118 and P= .874; Westfall-Young; data not shown).
Further, although statistically significant, the clinical relevance
of observed genetic effects can be questioned. According to recent
approaches, combining multiple genetic markers could provide
more reliable and meaningful prediction of antidepressant
response [29]. Nevertheless, several clinical and preclinical studies
implicated pathophysiological involvement of the neurotrophins in
antidepressant response [4,5,11–13]. We therefore argue, that a
thorough genetic approach with extended gene coverage like in
the present study can add to the understanding and characteriza-
tion of the neurotrophin system in antidepressant response
mechanisms.
Heterogeneity of patients is an important issue in genetic
association studies and may have limited the replication of initial
findings in the present study. In particular, we observed marked
differences in depression severity and response rates among
samples. In addition, besides unipolar depression, patients with a
bipolar disorder were included, which might have impaired the
homogeneity of our sample. Nevertheless, during a depressive
episode, there are no pathognomonic characteristics that can
reliably differentiate the two disorders and misdiagnosis of bipolar
disorder as unipolar depression occurs frequently [62,63]. Given a
relatively high annual conversion rate of recurrent unipolar to
bipolar disorder [64], these entities may indeed share common
disease mechanisms, too. Further, neither clinical data [1,64] nor
genetic analyses [29,65] support the view that these clinical entities
must be considered separately and a re-analysis with unipolar
patients only confirmed the initial findings. All patients fulfilled the
same inclusion criteria and did not differ in baseline demograph-
ics, duration of hospital stay and other characteristics of the
BDNF and NTRK2 and Antidepressant Treatment
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current episode. In addition, adjusting quantitative phenotype
variables for sample origin did not alter the SNP associations.
Four SNPs (rs2049046, rs6265, rs9969765 and rs11140793)
showed nominal deviations from the HWE (DHW) including the
most significantly associated SNP in the discovery analysis
(rs2049046). Using a Bonferroni-based threshold for multiple
testing of the HWE can be questioned and may not be
conservative enough. However, given that 82 SNPs have been
genotyped in the initial sample, false positive deviations of HWE
can be expected in about 4 cases for an alpha set to.05, which may
have been the case in the current analysis. DHW may also rely on
the underlying disease or phenotypic model itself and may thus be
regarded as an indicator of a true association (discussed in [66]).
Further, there was no indication for insufficient genotyping quality
as a possible explanation for DHW and deviations were only slight
(minimal P= .02) which has been reported in previous studies with
associated variants (e.g. [67]).
The current study does not have a placebo arm, making it
impossible to disentangle placebo-related and real pharmacolog-
ical effects, and only a part of our patients was treated with only
one class of antidepressant agent, increasing the risk of false-
positive and false-negative findings in the medication-specific
analyses. On the other hand, due to the naturalistic design of the
present study allowing medication of doctor’s choice, our results
are probably more generalizable and more relevant for clinical
practice. In addition, still a considerable number of patients
entered the medication-specific analysis and our findings are in
line with previous studies that reported BDNF SNP associations in
SSRI treated patients [19,23,50–52].
In summary, in an extended gene coverage approach, we found
variants in the NTRK2 gene that may potentially predict
antidepressant treatment outcome. Consistent with previous
reports, no major effect of the extensively studied BDNF Val66Met
polymorphism with antidepressant response could be found. The
functional impact of associated variants remains unclear and
replications of associations in subsequent studies including
functional assessments like RNA and protein measurements are
warrant to further substantiate initial findings of the present study.
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BDNF levels in non-improved (dark grey bars) and
improved patients (light grey bars). *P-values indicate
significant genotype6protein interactions as a predictor for
remission (rs10868223, A) or response (rs11140778, B; logistic
regression, age and sex as covariates).
(TIF)
Table S1 BDNF SNPs in the MARS discovery sample.
(DOC)
Table S2 NTRK2 SNPs in the MARS discovery sample.
(DOC)
Table S3 Effect of SSRI on SNP association.
(DOC)
Table S4 Association with response depending on
specific medication.
(DOC)
Table S5 Effect of gender on SNP association.
(DOC)
Table S6 Haplotypes Associated with Response after 5
Weeks.
(DOC)
Document S1 Medication- and gender-specific associa-
tion.
(DOC)
Acknowledgments
We thank Florian Holsboer for fruitful discussion and many helpful
comments during the course of the project. We are grateful to Gertrud
Ernst-Jansen, Beate Siegel, Melanie Huber, Elisabeth Kappelmann, Maik
Ko¨del and Susann Sauer for excellent technical assistance. Excellent
support in data bank management was provided by Hildegard Pfister and
Benno Pu¨tz.
Author Contributions
Conceived and designed the experiments: JH MK SL. Performed the
experiments: JH TB SH TK SL AM MG AE MU. Analyzed the data: JH
DC CW AH MI BM. Contributed reagents/materials/analysis tools: KD
VA BB MG AE. Wrote the paper: JH SL.
References
1. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, et al. (2009)
Clinical characteristics and treatment outcome in a representative sample of
depressed inpatients - findings from the Munich Antidepressant Response
Signature (MARS) project. J Psychiatr Res 43: 215–229.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. (2006)
Acute and longer-term outcomes in depressed outpatients requiring one or
several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905–1917.
3. Holsboer F (2000) The corticosteroid receptor hypothesis of depression.
Neuropsychopharmacology 23: 477–501.
4. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related
mood disorders. Biol Psychiatry 59: 1116–1127.
5. Groves JO (2007) Is it time to reassess the BDNF hypothesis of depression? Mol
Psychiatry 12: 1079–1088.
6. Schaaf MJ, de Jong J, de Kloet ER, Vreugdenhil E (1998) Downregulation of
BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res
813: 112–120.
7. Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids
affect the expression of brain-derived neurotrophic factor and neurotrophin-3
mRNAs in the hippocampus. J Neurosci 15: 1768–1777.
8. Poo MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2: 24–
32.
9. Kozisek ME, Middlemas D, Bylund DB (2008) Brain-derived neurotrophic
factor and its receptor tropomyosin-related kinase B in the mechanism of action
of antidepressant therapies. Pharmacol Ther 117: 30–51.
10. Sillaber I, Panhuysen M, Henniger MSH, Ohl F, Ku¨hne C, et al. (2008)
Profiling of behavioral changes and hippocampal gene expression in mice
chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 200:
557–572.
BDNF and NTRK2 and Antidepressant Treatment
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e64947
11. Dwivedi Y (2009) Brain-derived neurotrophic factor: role in depression and
suicide. Neuropsychiatr Dis Treat 5: 433–449.
12. Knapman A, Heinzmann J-M, Hellweg R, Holsboer F, Landgraf R, et al. (2010)
Increased stress reactivity is associated with cognitive deficits and decreased
hippocampal brain-derived neurotrophic factor in a mouse model of affective
disorders. J Psychiatr Res 44: 566–575.
13. Tadic´ A, Wagner S, Schlicht KF, Peetz D, Borysenko L, et al. (2011) The early
non-increase of serum BDNF predicts failure of antidepressant treatment in
patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol
Psychiatry 35: 415–420.
14. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, et al. (2003)
Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs
and is required for antidepressant-induced behavioral effects. J Neurosci 23:
349–357.
15. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB
mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug
treatments. J Neurosci 15: 7539–7547.
16. Rantama¨ki T, Knuuttila JEA, Hokkanen M-E, Castre´n E (2006) The effects of
acute and long-term lithium treatments on trkB neurotrophin receptor activation
in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology
50: 421–427.
17. Rantama¨ki T, Hendolin P, Kankaanpa¨a¨ A, Mijatovic J, Piepponen P, et al.
(2007) Pharmacologically diverse antidepressants rapidly activate brain-derived
neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling
pathways in mouse brain. Neuropsychopharmacology 32: 2152–2162.
18. Kato M, Serretti A (2008) Review and meta-analysis of antidepressant
pharmacogenetic findings in major depressive disorder. Mol Psychiatry.
Available: http://www.ncbi.nlm.nih.gov/pubmed/18982004. Accessed 2009
Sep 15.
19. Zou Y-F, Wang Y, Liu P, Feng X-L, Wang B-Y, et al. (2010) Association of
brain-derived neurotrophic factor genetic Val66Met polymorphism with severity
of depression, efficacy of fluoxetine and its side effects in Chinese major
depressive patients. Neuropsychobiology 61: 71–78.
20. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, et al. (2010) Population
genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol
Psychiatry 15: 810–815.
21. Dong C, Wong M-L, Licinio J (2009) Sequence variations of ABCB1, SLC6A2,
SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major
depression and antidepressant response in Mexican-Americans. Mol Psychiatry
14: 1105–1118.
22. Licinio J, Dong C, Wong M-L (2009) Novel sequence variations in the brain-
derived neurotrophic factor gene and association with major depression and
antidepressant treatment response. Arch Gen Psychiatry 66: 488–497.
23. Domschke K, Lawford B, Laje G, Berger K, Young R, et al. (2009) Brain-
derived neurotrophic factor (BDNF) gene: no major impact on antidepressant
treatment response. Int J Neuropsychopharmacol: 1–9.
24. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, et al. (2006)
Variation in the gene encoding the serotonin 2A receptor is associated with
outcome of antidepressant treatment. Am J Hum Genet 78: 804–814.
25. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, et al. (2008)
Association of the COMT val158 met variant with antidepressant treatment
response in major depression. Neuropsychopharmacology 33: 924–932.
26. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, et al. (2004)
Polymorphisms in FKBP5 are associated with increased recurrence of depressive
episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319–
1325.
27. Horstmann S, Dose T, Lucae S, Kloiber S, Menke A, et al. (2009) Suppressive
effect of mirtazapine on the HPA system in acutely depressed women seems to
be transient and not related to antidepressant action. Psychoneuroendocrinology
34: 238–248.
28. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, et al. (2007) Combined
dexamethasone/corticotropin releasing hormone test predicts treatment re-
sponse in major depression - a potential biomarker? Biol Psychiatry 62: 47–54.
doi:10.1016/j.biopsych.2006.07.039.
29. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, et al. (2009) A Genomewide
Association Study Points to Multiple Loci That Predict Antidepressant Drug
Treatment Outcome in Depression. Arch Gen Psychiatry 66: 966–975.
30. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, et al. (2008)
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant
treatment response in depression. Neuron 57: 203–209.
31. Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, et al. (2010)
Association of genetic variants in the neurotrophic receptor-encoding gene
NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch
Gen Psychiatry 67: 348–359.
32. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more
efficient than replication-based analysis for two-stage genome-wide association
studies. Nat Genet 38: 209–213.
33. Colhoun H, Mckeigue P, Smith G (2003) Problems of reporting genetic
associations with complex outcomes. The Lancet 361: 865–872.
34. Westfall P, Young S (1993) Resampling-Based Multiple Testing: Examples and
Methods for P-Value Adjustment. New York, NY: John Wiley & Sons.
35. North BV, Curtis D, Sham PC (2002) A Note on the Calculation of Empirical P
Values from Monte Carlo Procedures. Am J Hum Genet 71: 439–441.
36. Armitage P (1955) Tests for Linear Trends in Proportions and Frequencies.
Biometrics 11: 375–386.
37. Fisher RA (1932) Statistical methods for research workers. 4th ed. London:
Oliver & Boyd.
38. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
39. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The
structure of haplotype blocks in the human genome. Science 296: 2225–2229.
40. Adams JH, Wigg KG, King N, Burcescu I, Vetro´ A, et al. (2005) Association
study of neurotrophic tyrosine kinase receptor type 2 (NTRK2) and childhood-
onset mood disorders. Am J Med Genet B Neuropsychiatr Genet 132B: 90–95.
41. Grataco`s M, Soria V, Urretavizcaya M, Gonza´lez JR, Crespo JM, et al. (2008) A
brain-derived neurotrophic factor (BDNF) haplotype is associated with
antidepressant treatment outcome in mood disorders. Pharmacogenomics J 8:
101–112.
42. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, et al. (2011) Brain-
derived neurotrophic factor gene polymorphisms: influence on treatment
response phenotypes of major depressive disorder. Int Clin Psychopharmacol
26: 1–10.
43. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, et al. (2012)
Patterns of Cis Regulatory Variation in Diverse Human Populations. PLoS
Genet 8: e1002639.
44. Alonso P, Grataco`s M, Mencho´n JM, Saiz-Ruiz J, Segala`s C, et al. (2008)
Extensive genotyping of the BDNF and NTRK2 genes define protective
haplotypes against obsessive-compulsive disorder. Biol Psychiatry 63: 619–628.
45. Cozza A, Melissari E, Iacopetti P, Mariotti V, Tedde A, et al. (2008) SNPs in
neurotrophin system genes and Alzheimer’s disease in an Italian population.
J Alzheimers Dis 15: 61–70.
46. Perroud N, Aitchison KJ, Uher R, Smith R, Huezo-Diaz P, et al. (2009) Genetic
Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in
the GENDEP Project. Neuropsychopharmacology. Available: http://www.ncbi.
nlm.nih.gov/pubmed/19641488. Accessed 16 September 2009.
47. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, et al. (2009) Genetic
predictors of response to antidepressants in the GENDEP project.
Pharmacogenomics J 9: 225–233.
48. Lin E, Hong C-J, Hwang J-P, Liou Y-J, Yang C-H, et al. (2009) Gene-gene
interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine
kinase receptor 2 genes in geriatric depression. Rejuvenation Res 12: 387–393.
49. Dwivedi Y, Rizavi HS, Pandey GN (2006) Antidepressants reverse corticoste-
rone-mediated decrease in brain-derived neurotrophic factor expression:
differential regulation of specific exons by antidepressants and corticosterone.
Neuroscience 139: 1017–1029.
50. Choi M-J, Kang R-H, Lim S-W, Oh K-S, Lee M-S (2006) Brain-derived
neurotrophic factor gene polymorphism (Val66Met) and citalopram response in
major depressive disorder. Brain Res 1118: 176–182.
51. Kang R, Chang H, Wong M, Choi M, Park J, et al. (2009) Brain-derived
neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans
with major depression. J Psychopharmacol (Oxford). Available: http://www.
ncbi.nlm.nih.gov/pubmed/19493959. Accessed 2009 Sep 14.
52. Tsai S-J, Hong C-J, Liou Y-J (2008) Brain-derived neurotrophic factor and
antidepressant action: another piece of evidence from pharmacogenetics.
Pharmacogenomics 9: 1353–1358.
53. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, et al. (2005) Evidence
for a relationship between genetic variants at the brain-derived neurotrophic
factor (BDNF) locus and major depression. Biol Psychiatry 58: 307–314.
54. Taylor WD, McQuoid DR, Ashley-Koch A, Macfall JR, Bridgers J, et al. (2010)
BDNF Val66Met genotype and 6-month remission rates in late-life depression.
Pharmacogenomics J. Available: http://www.ncbi.nlm.nih.gov/pubmed/
20195291. Accessed 2011 Jan 25.
55. Wilkie MJV, Smith D, Reid IC, Day RK, Matthews K, et al. (2007) A splice site
polymorphism in the G-protein beta subunit influences antidepressant efficacy in
depression. Pharmacogenet Genomics 17: 207–215.
56. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, et al. (2007) The
G196A polymorphism of the brain-derived neurotrophic factor gene and the
antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol
(Oxford) 21: 650–656.
57. Verhagen M, van der Meij A, van Deurzen PAM, Janzing JGE, Arias-Va´squez
A, et al. (2010) Meta-analysis of the BDNF Val66Met polymorphism in major
depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15: 260–271.
58. Hong C-J, Huo S-J, Yen F-C, Tung C-L, Pan G-M, et al. (2003) Association
study of a brain-derived neurotrophic-factor genetic polymorphism and mood
disorders, age of onset and suicidal behavior. Neuropsychobiology 48: 186–189.
59. Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, et al. (2004) No
association between the Val66Met polymorphism of the brain-derived
neurotrophic factor gene and bipolar disorder in a Japanese population: a
multicenter study. Biol Psychiatry 56: 376–378.
60. Nakata K, Ujike H, Sakai A, Uchida N, Nomura A, et al. (2003) Association
study of the brain-derived neurotrophic factor (BDNF) gene with bipolar
disorder. Neurosci Lett 337: 17–20.
61. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, et al. (2002) The
brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder:
evidence from a family-based association study. Am J Hum Genet 71: 651–655.
62. Ghaemi SN, Ko JY, Goodwin FK (2001) The bipolar spectrum and the
antidepressant view of the world. J Psychiatr Pract 7: 287–297.
BDNF and NTRK2 and Antidepressant Treatment
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e64947
63. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RMA (2008) Diagnostic
guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 10:
144–152.
64. Angst J, Sellaro R, Stassen HH, Gamma A (2005) Diagnostic conversion from
depression to bipolar disorders: results of a long-term prospective study of
hospital admissions. J Affect Disord 84: 149–157.
65. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, et al. (2010) Meta-
analysis of genome-wide association data identifies a risk locus for major mood
disorders on 3p21.1. Nat Genet 42: 128–131.
66. Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, et al. (2006)
Polymorphisms in the angiotensin-converting enzyme gene are associated with
unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 11:
1003–1015.
67. Wittke-Thompson JK, Pluzhnikov A, Cox NJ (2005) Rational inferences about
departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76: 967–986.
BDNF and NTRK2 and Antidepressant Treatment
PLOS ONE | www.plosone.org 12 June 2013 | Volume 8 | Issue 6 | e64947
